Parabilis Medicines Inc.
PBLS | NASDAQ
$28.32
-$0.38 (-1.32%)
At close: Oct 30, 2026, 4:00 PM ET
$28.53
+$0.21 (+0.74%)
Pre-market:
Nov 2, 2026, 7:53 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | n/a | n/a |
Gross Profit | n/a | n/a |
Operating Income | -152.08M | -126.13M |
Interest Income | 3.39M | 6.41M |
Pretax Income | -145.89M | -117.91M |
Net Income | -145.89M | -117.91M |
Selling & General & Admin | 26.5M | 25.3M |
Research & Development | 125.58M | 100.83M |
Other Expenses | n/a | n/a |
Operating Expenses | 152.08M | 126.13M |
Interest Expense | 1.52M | 1.49M |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 152.08M | 126.13M |
Income Tax Expense | n/a | n/a |
Shares Outstanding (Basic) | 2.02M | 1.93M |
Shares Outstanding (Diluted) | 2.02M | 1.93M |
EPS (Basic) | -92.40 | -83.48 |
EPS (Diluted) | -92.40 | -83.48 |
EBITDA | -141.87M | -114.33M |
EBIT | -144.37M | -116.43M |
Depreciation & Amortization | 2.5M | 2.1M |
Add to Watchlist
Select watchlists to add or remove PBLS